Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | SDHA | P31040 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CALML3 | P27482 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3367287 | 1.00 | MAOA (0.44) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL14012749 | 0.93 | MAOA (0.50) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3368324 | 0.93 | MAOA (0.50) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3366199 | 0.90 | ABCB11 (0.42) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL13711574 | 0.90 | ABCB11 (0.42) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL13711568 | 0.88 | MAOA (0.46) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL13334913 | 0.88 | MAOA (0.46) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3366992 | 0.88 | MAOA (0.46) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL13711534 | 0.88 | GPR119 (0.35) | MAOAMAOB | |
| SCHEMBL13335261 | 0.88 | MAOA (0.49) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582659-B2 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO., INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7462633-B2 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO., INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20070203187-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO., INC. (US) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203187-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | OXA1L, ALAD, COASY | MAOA 2977/4885MAOB 1835/4885PTGS1 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.